NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price, Price Target & More

$82.51 +0.98 (+1.20 %)
(As of 04/26/2018 04:00 PM ET)
Previous Close$81.53
Today's Range$80.03 - $84.43
52-Week Range$75.81 - $100.51
Volume1.64 million shs
Average Volume1.35 million shs
Market Capitalization$14.28 billion
P/E Ratio-123.15
Dividend YieldN/A
Beta1.69

About BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical logoBioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BMRN
CUSIP09061G10
Phone415-506-6700

Debt

Debt-to-Equity Ratio0.29%
Current Ratio2.70%
Quick Ratio2.12%

Price-To-Earnings

Trailing P/E Ratio-123.15
Forward P/E Ratio-515.69
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.31 billion
Price / Sales11.06
Cash FlowN/A
Price / CashN/A
Book Value$15.99 per share
Price / Book5.16

Profitability

EPS (Most Recent Fiscal Year)($0.67)
Net Income$-117,040,000.00
Net Margins-8.91%
Return on Equity-3.18%
Return on Assets-2.07%

Miscellaneous

Employees2,581
Outstanding Shares176,070,000

How to Become a New Pot Stock Millionaire

BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical (NASDAQ:BMRN) issued its earnings results on Thursday, February, 22nd. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.06. The biotechnology company had revenue of $358.31 million for the quarter, compared to analyst estimates of $346.24 million. BioMarin Pharmaceutical had a negative net margin of 8.91% and a negative return on equity of 3.18%. View BioMarin Pharmaceutical's Earnings History.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for BioMarin Pharmaceutical.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY18 earnings guidance on Wednesday, April, 25th. The company provided EPS guidance of $0.57-0.79 for the period, compared to the Thomson Reuters consensus estimate of $0.70. The company issued revenue guidance of $1.47-1.53 billion, compared to the consensus revenue estimate of $1.49 billion.

What price target have analysts set for BMRN?

19 Wall Street analysts have issued 12-month target prices for BioMarin Pharmaceutical's stock. Their predictions range from $89.00 to $150.00. On average, they anticipate BioMarin Pharmaceutical's share price to reach $113.8421 in the next twelve months. View Analyst Ratings for BioMarin Pharmaceutical.

What are Wall Street analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "BioMarin’s key orphan disease drugs – Vimizim and Kuvan – continue to do well, backed by strong underlying patient demand trends. BioMarin expects sustained growth in both the drugs. Brineura’s earlier-than-expected approval was also a huge boost for BioMarin. Its impressive rare-disease pipeline is also progressing well with approval for pegvaliase expected in 2018. However, BioMarin has suffered a few regulatory setbacks related to its pipeline candidates in the past. Further development setbacks can have a negative impact on the stock. Also, Naglazyme and Vimzin revenues vary on a quarterly basis primarily due to infrequent ordering patterns from some countries, mainly Brazil. The stock has also underperformed the industry in the past year. Earnings estimates have increased ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in recent quarters." (4/25/2018)
  • 2. JPMorgan Chase analysts commented, "BMRN’s 4Q print was largely in-line; the company also provided 2018 guidance that bracketed consensus revenue expectations. There was some incremental color on regulatory (pegvaliase) and commercial (Brineura/pegvaliase) progress / expectations for emerging products. Importantly, the pipeline continues on track, and 2019 looks to be a critical year on that front. We anticipate interest in BMRN will increase materially as we eventually get closer to the pivotal data for val rox and vosoritide. Reiterate OW." (2/25/2018)
  • 3. Cowen Inc analysts commented, "New data include 52 wk follow-up on all patients at BMN270’s 6e13 vg/kg dose, and." (7/11/2017)

Who are some of BioMarin Pharmaceutical's key competitors?

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the folowing people:
  • Mr. Jean-Jacques Bienaimé, Chairman & CEO (Age 65)
  • Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 59)
  • Dr. Robert A. Baffi Ph.D., MBA, Exec. VP of Technical Operations (Age 63)
  • Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 56)
  • Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 60)

Has BioMarin Pharmaceutical been receiving favorable news coverage?

News coverage about BMRN stock has trended somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioMarin Pharmaceutical earned a media sentiment score of 0.04 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 45.34 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include PRUDENTIAL FINANCIAL INC (6.80%) and PRIMECAP MANAGEMENT COMPANY (5.86%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $82.51.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $14.28 billion and generates $1.31 billion in revenue each year. The biotechnology company earns $-117,040,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. BioMarin Pharmaceutical employs 2,581 workers across the globe.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]


MarketBeat Community Rating for BioMarin Pharmaceutical (BMRN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  948 (Vote Outperform)
Underperform Votes:  463 (Vote Underperform)
Total Votes:  1,411
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for BioMarin Pharmaceutical in the last 12 months. Their average twelve-month price target is $113.8421, suggesting that the stock has a possible upside of 37.97%. The high price target for BMRN is $150.00 and the low price target for BMRN is $89.00. There are currently 4 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.842.842.772.70
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $113.8421$113.8421$112.95$112.2727
Price Target Upside: 37.97% upside35.83% upside22.25% upside36.07% upside

BioMarin Pharmaceutical (NASDAQ:BMRN) Consensus Price Target History

Price Target History for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ:BMRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018Credit Suisse GroupReiterated RatingBuy$116.00MediumView Rating Details
3/12/2018WedbushReiterated RatingOutperform$110.00MediumView Rating Details
2/27/2018Royal Bank of CanadaReiterated RatingHold$94.00MediumView Rating Details
2/25/2018JPMorgan ChaseReiterated RatingBuyLowView Rating Details
2/23/2018Morgan StanleyLower Price TargetOverweight -> Overweight$115.00 -> $112.00MediumView Rating Details
2/23/2018Stifel NicolausLower Price TargetBuy -> Buy$105.00 -> $102.00HighView Rating Details
2/23/2018Leerink SwannLower Price TargetOutperform -> Outperform$142.00 -> $132.00HighView Rating Details
2/23/2018BMO Capital MarketsReiterated RatingOutperform -> Outperform$119.00 -> $125.00HighView Rating Details
2/23/2018Deutsche BankSet Price TargetBuy -> Buy$119.00 -> $124.00HighView Rating Details
1/18/2018Piper JaffrayReiterated RatingBuy$114.00LowView Rating Details
12/15/2017Goldman SachsUpgradeBuy -> Conviction-BuyHighView Rating Details
12/11/2017SunTrust BanksBoost Price TargetBuy$130.00HighView Rating Details
9/26/2017Jefferies GroupReiterated RatingBuy$116.00LowView Rating Details
8/31/2017CitigroupInitiated CoverageBuy -> Buy$98.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$100.00HighView Rating Details
8/4/2017CowenReiterated RatingBuyLowView Rating Details
8/3/2017UBSReiterated RatingNeutral$92.00 -> $93.00LowView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$89.00HighView Rating Details
7/22/2017BarclaysReiterated RatingEqual Weight$105.00 -> $100.00LowView Rating Details
3/1/2017InstinetInitiated CoverageNeutral -> Neutral$93.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
2/10/2017GabelliReiterated RatingBuyN/AView Rating Details
1/9/2017Robert W. BairdSet Price TargetBuy$115.00N/AView Rating Details
7/28/2016William BlairSet Price TargetBuy$116.00N/AView Rating Details
6/20/2016OppenheimerReiterated RatingMarket Perform$99.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

BioMarin Pharmaceutical (NASDAQ:BMRN) Earnings History and Estimates Chart

Earnings by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ:BMRN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.59)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($0.26)$0.17($0.11)
Q2 20183($0.19)($0.16)($0.18)
Q3 20184($0.21)($0.10)($0.15)
Q4 20183($0.20)($0.04)($0.15)

BioMarin Pharmaceutical (NASDAQ BMRN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018        
4/25/2018Q1 2018($0.17)($0.25)$348.73 million$373.45 millionViewN/AView Earnings Details
2/22/2018Q4 2017($0.24)($0.30)$346.24 million$358.31 millionViewN/AView Earnings Details
10/26/2017Q3 2017($0.13)($0.07)$347.38 million$334.18 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.22)($0.21)$311.41 million$317.50 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.30)$0.03$292.58 million$303.70 millionViewListenView Earnings Details
2/23/2017Q416($0.38)($0.53)$296.54 million$300.00 millionViewN/AView Earnings Details
10/27/2016Q316($0.39)($0.13)$289.70 million$279.90 millionViewListenView Earnings Details
8/4/2016Q216($0.52)($2.61)$278.75 million$300.10 millionViewN/AView Earnings Details
4/28/2016Q116($0.85)($0.53)$240.21 million$236.70 millionViewListenView Earnings Details
2/25/2016Q415$0.67$0.39$224.14 million$227.90 millionViewListenView Earnings Details
10/29/2015Q315($0.65)($0.60)$216.32 million$208.90 millionViewListenView Earnings Details
8/3/2015Q215($0.53)($0.22)$218.16 million$250.50 millionViewN/AView Earnings Details
4/30/2015Q1($0.53)($0.25)$204.58 million$203.26 millionViewN/AView Earnings Details
2/25/2015Q414($0.59)($0.30)$189.01 million$230.90 millionViewN/AView Earnings Details
10/23/2014Q314($0.22)($0.16)$206.00 million$176.80 millionViewListenView Earnings Details
7/30/2014Q214($0.42)($0.19)$159.70 million$191.70 millionViewN/AView Earnings Details
5/1/2014Q1 2014($0.50)($0.27)$145.16 million$151.60 millionViewN/AView Earnings Details
2/26/2014Q413($0.35)($0.11)$146.07 million$146.90 millionViewN/AView Earnings Details
10/24/2013Q313($0.30)($0.38)$140.00 million$136.90 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.29)($0.16)$134.33 million$136.80 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.30)($0.31)$131.35 million$127.90 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.22)($0.43)$129.70 million$130.96 millionViewN/AView Earnings Details
10/25/2012($0.20)($0.04)ViewN/AView Earnings Details
8/1/2012($0.19)($0.27)ViewN/AView Earnings Details
4/26/2012($0.15)($0.21)ViewN/AView Earnings Details
2/16/2012($0.10)($0.23)ViewN/AView Earnings Details
10/27/2011($0.10)($0.16)ViewN/AView Earnings Details
7/28/2011($0.09)($0.05)ViewN/AView Earnings Details
4/28/2011($0.10)$0.14ViewN/AView Earnings Details
2/17/2011($0.02)($0.11)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.02)($0.03)ViewN/AView Earnings Details
8/2/2010Q2 2010$0.02($0.01)ViewN/AView Earnings Details
4/29/2010Q1 2010$0.01ViewN/AView Earnings Details
2/23/2010Q4 2009$0.05ViewN/AView Earnings Details
10/28/2009Q3 2009$0.06ViewN/AView Earnings Details
4/30/2009Q1 2009($0.12)($0.13)ViewN/AView Earnings Details
2/18/2009Q4 2008$0.24$0.24ViewN/AView Earnings Details
10/28/2008Q3 2008$0.03$0.01ViewN/AView Earnings Details
8/5/2008Q2 2008$0.02$0.04ViewN/AView Earnings Details
4/29/2008Q1 2008($0.04)$0.02ViewN/AView Earnings Details
2/26/2008Q4 2007$0.04$0.03ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

BioMarin Pharmaceutical (NASDAQ:BMRN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BioMarin Pharmaceutical (NASDAQ BMRN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.85%
Insider Trading History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ BMRN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/24/2018Jean Jacques BienaimeCEOSell20,000$82.43$1,648,600.00300,031View SEC Filing  
4/23/2018Daniel K SpiegelmanCFOSell11,059$82.15$908,496.8562,543View SEC Filing  
4/20/2018Jean Jacques BienaimeCEOSell10,000$83.65$836,500.00300,031View SEC Filing  
4/17/2018V Bryan LawlisDirectorSell3,750$85.00$318,750.0018,610View SEC Filing  
4/2/2018Henry J FuchsInsiderSell10,000$80.12$801,200.00160,026View SEC Filing  
4/2/2018Jeffrey Robert AjerEVPSell2,119$80.12$169,774.2852,914View SEC Filing  
3/29/2018Jeffrey Robert AjerEVPSell1,537$79.69$122,483.5355,033View SEC Filing  
3/23/2018George Eric DavisEVPSell3,350$81.35$272,522.5087,989View SEC Filing  
3/21/2018Jeffrey Robert AjerEVPSell4,368$83.90$366,475.2060,153View SEC Filing  
3/16/2018George Eric DavisEVPSell3,818$83.88$320,253.8494,634View SEC Filing  
3/15/2018Jean Jacques BienaimeCEOSell15,000$84.73$1,270,950.00279,674View SEC Filing  
3/9/2018Jeffrey Robert AjerEVPSell2,972$82.39$244,863.0855,332View SEC Filing  
3/5/2018George Eric DavisEVPSell2,105$79.04$166,379.2090,089View SEC Filing  
2/15/2018Jean Jacques BienaimeCEOSell10,000$84.63$846,300.00View SEC Filing  
2/1/2018George Eric DavisEVPSell30,000$90.66$2,719,800.00112,942View SEC Filing  
1/5/2018Jean Jacques BienaimeCEOSell10,000$90.32$903,200.00235,894View SEC Filing  
1/2/2018Henry J. FuchsInsiderSell15,000$89.23$1,338,450.00View SEC Filing  
1/2/2018V Bryan LawlisDirectorSell3,750$88.84$333,150.00View SEC Filing  
12/29/2017Jean Jacques BienaimeCEOSell20,000$89.75$1,795,000.00View SEC Filing  
12/29/2017Jean Jacques BienaimeCEOSell10,000$89.61$896,100.00226,494View SEC Filing  
12/14/2017Elaine J HeronDirectorSell800$88.90$71,120.0038,385View SEC Filing  
11/30/2017George Eric DavisEVPSell1,200$85.64$102,768.00View SEC Filing  
9/28/2017Robert BaffiEVPSell18,415$92.43$1,702,098.45129,083View SEC Filing  
9/22/2017Jeffrey Robert AjerEVPSell3,521$95.00$334,495.0049,299View SEC Filing  
9/15/2017Henry J FuchsInsiderSell15,000$90.50$1,357,500.00141,422View SEC Filing  
9/15/2017V Bryan LawlisDirectorSell3,750$91.26$342,225.0019,660View SEC Filing  
6/23/2017George Eric DavisEVPSell9,844$96.60$950,930.4093,425View SEC Filing  
6/22/2017Brian MuellerSVPSell2,671$100.00$267,100.0015,556View SEC Filing  
6/19/2017Henry J FuchsInsiderSell15,000$90.00$1,350,000.00141,422View SEC Filing  
6/16/2017V Bryan LawlisDirectorSell3,750$90.00$337,500.0019,660View SEC Filing  
6/7/2017Jeffrey Robert AjerEVPSell1,004$89.61$89,968.4447,944View SEC Filing  
6/5/2017George Eric DavisEVPSell9,471$91.04$862,239.8474,342View SEC Filing  
6/5/2017Jean Jacques BienaimeCEOSell10,000$90.13$901,300.00238,564View SEC Filing  
5/24/2017Jean Jacques BienaimeCEOSell5,000$88.38$441,900.00238,564View SEC Filing  
5/17/2017Jean Jacques BienaimeCEOSell5,000$91.73$458,650.00238,564View SEC Filing  
5/8/2017Brian MuellerSVPSell7,482$91.87$687,371.3418,350View SEC Filing  
5/8/2017Jean Jacques BienaimeCEOSell10,000$96.09$960,900.00238,496View SEC Filing  
5/5/2017George Eric DavisEVPSell2,500$100.34$250,850.0085,251View SEC Filing  
5/2/2017Jeffrey Robert AjerEVPSell302$96.74$29,215.4851,834View SEC Filing  
4/27/2017Jean Jacques BienaimeCEOSell5,000$95.72$478,600.00243,194View SEC Filing  
4/25/2017Jean Jacques BienaimeCEOSell5,000$94.00$470,000.00243,194View SEC Filing  
3/29/2017Jeffrey Robert AjerEVPSell3,890$89.15$346,793.5051,532View SEC Filing  
3/16/2017Daniel K SpiegelmanCFOSell1,989$91.96$182,908.4416,460View SEC Filing  
3/16/2017George Eric DavisEVPSell2,238$91.96$205,806.4875,967View SEC Filing  
3/16/2017Jean Jacques BienaimeCEOSell10,000$91.69$916,900.00211,364View SEC Filing  
3/10/2017Jean Jacques BienaimeCEOSell11,000$90.59$996,490.00212,364View SEC Filing  
3/7/2017Jeffrey Robert AjerEVPSell5,000$90.56$452,800.0046,510View SEC Filing  
3/6/2017Daniel K SpiegelmanCFOSell2,303$93.32$214,915.9620,761View SEC Filing  
3/6/2017George Eric DavisEVPSell1,498$93.32$139,793.3678,962View SEC Filing  
3/1/2017Daniel K SpiegelmanCFOSell35,000$94.07$3,292,450.0060,347View SEC Filing  
3/1/2017V Bryan LawlisDirectorSell7,500$95.00$712,500.0021,360View SEC Filing  
2/24/2017Henry J FuchsInsiderSell15,000$87.99$1,319,850.00128,442View SEC Filing  
1/26/2017Jean Jacques BienaimeCEOSell10,000$84.22$842,200.00175,682View SEC Filing  
1/11/2017Jean Jacques BienaimeCEOSell8,000$90.58$724,640.00174,682View SEC Filing  
1/9/2017Daniel K SpiegelmanCFOSell5,000$90.00$450,000.0018,100View SEC Filing  
1/9/2017Jean Jacques BienaimeCEOSell8,000$88.49$707,920.00174,682View SEC Filing  
12/30/2016Jean Jacques BienaimeCEOSell8,000$83.60$668,800.00174,682View SEC Filing  
11/22/2016Jean Jacques BienaimeCEOSell69,743$85.69$5,976,277.67View SEC Filing  
11/21/2016Jean Jacques BienaimeCEOSell69,744$87.56$6,106,784.64View SEC Filing  
11/8/2016Jean Jacques BienaimeCEOSell140,000$82.67$11,573,800.00393,368View SEC Filing  
11/7/2016Jean Jacques BienaimeCEOSell70,000$82.52$5,776,400.00393,368View SEC Filing  
10/28/2016Jean Jacques BienaimeCEOSell120,000$81.30$9,756,000.00383,368View SEC Filing  
10/17/2016Jean Jacques BienaimeCEOSell41,666$84.39$3,516,193.74365,034View SEC Filing  
10/14/2016Jean Jacques BienaimeCEOSell64,125$86.96$5,576,310.00378,184View SEC Filing  
9/29/2016Jean Jacques BienaimeCEOSell53,125$93.65$4,975,156.25431,709View SEC Filing  
9/27/2016Jeffrey Robert AjerEVPSell18,467$95.61$1,765,629.8741,342View SEC Filing  
9/16/2016Jean Jacques BienaimeCEOSell137,368$95.34$13,096,665.12421,161View SEC Filing  
8/26/2016Henry J FuchsEVPSell15,000$95.06$1,425,900.00128,878View SEC Filing  
8/16/2016Jean Jacques BienaimeCEOSell41,666$91.49$3,812,022.34420,250View SEC Filing  
8/1/2016Brian MuellerVPSell287$100.00$28,700.0014,260View SEC Filing  
8/1/2016Daniel K SpiegelmanCFOSell4,000$99.33$397,320.0042,944View SEC Filing  
8/1/2016George Eric DavisEVPSell2,167$100.00$216,700.0071,158View SEC Filing  
7/27/2016V Bryan LawlisDirectorSell1,100$95.39$104,929.0014,960View SEC Filing  
7/22/2016V Bryan LawlisDirectorSell6,400$95.01$608,064.0020,260View SEC Filing  
7/18/2016Jean Jacques BienaimeCEOSell41,666$92.72$3,863,271.52420,250View SEC Filing  
7/7/2016George Eric DavisEVPSell2,167$90.00$195,030.0072,836View SEC Filing  
6/20/2016V Bryan LawlisDirectorSell550$82.77$45,523.5013,860View SEC Filing  
6/16/2016Jean Jacques BienaimeCEOSell41,666$80.55$3,356,196.30420,250View SEC Filing  
6/6/2016Daniel K SpiegelmanCFOSell1,649$89.14$146,991.8646,944View SEC Filing  
5/31/2016Daniel K SpiegelmanCFOSell20,841$89.88$1,873,189.0871,235View SEC Filing  
5/26/2016Henry J FuchsEVPSell15,000$87.81$1,317,150.00130,914View SEC Filing  
5/23/2016Daniel K SpiegelmanCFOSell3,769$87.07$328,166.8358,644View SEC Filing  
5/18/2016Robert BaffiEVPSell5,000$87.05$435,250.00130,386View SEC Filing  
5/10/2016George Eric DavisEVPSell14,658$85.11$1,247,542.3891,894View SEC Filing  
5/5/2016Jean Jacques BienaimeCEOSell50,000$80.15$4,007,500.00390,156View SEC Filing  
5/3/2016Jeffrey Robert AjerEVPSell415$86.03$35,702.4563,487View SEC Filing  
5/2/2016Jean Jacques BienaimeCEOSell36,500$85.01$3,102,865.00395,635View SEC Filing  
3/14/2016George Eric DavisEVPSell1,996$86.21$172,075.1676,190View SEC Filing  
3/4/2016Jeffrey Robert AjerSVPSell1,255$88.42$110,967.1048,137View SEC Filing  
3/2/2016Daniel K SpiegelmanCFOSell4,623$86.12$398,132.7654,311View SEC Filing  
3/1/2016Jean Jacques BienaimeCEOSell10,000$84.28$842,800.00350,500View SEC Filing  
2/22/2016Michael G GreyDirectorSell7,500$80.00$600,000.0033,750View SEC Filing  
12/16/2015George Eric DavisSVPSell1,362$100.00$136,200.0066,156View SEC Filing  
11/30/2015Jean Jacques BienaimeCEOSell1,000$94.74$94,740.00228,754View SEC Filing  
11/16/2015Daniel K. SpiegelmanCFOSell20,000$104.30$2,086,000.0028,229View SEC Filing  
11/16/2015V Bryan LawlisDirectorSell8,550$106.90$913,995.0011,850View SEC Filing  
10/15/2015Jean Jacques BienaimeCEOSell1,000$108.24$108,240.00228,754View SEC Filing  
9/14/2015Jean Jacques BienaimeCEOSell1,000$131.43$131,430.00228,754View SEC Filing  
7/20/2015Jeffrey Robert AjerSVPSell3,000$150.00$450,000.00View SEC Filing  
7/7/2015Jean Jacques BienaimeCEOSell1,500$139.07$208,605.00View SEC Filing  
6/5/2015Daniel K SpiegelmanCFOSell1,649$122.30$201,672.70View SEC Filing  
6/5/2015Henry J FuchsEVPSell1,864$122.32$228,004.48View SEC Filing  
6/4/2015Jeffrey Robert AjerSVPSell1,362$122.35$166,640.70View SEC Filing  
6/1/2015Daniel K SpiegelmanCFOSell5,523$124.73$688,883.79View SEC Filing  
6/1/2015Jeffrey Robert AjerSVPSell377$123.76$46,657.52View SEC Filing  
5/29/2015Daniel K SpiegelmanCFOSell1,578$126.15$199,064.70View SEC Filing  
5/26/2015Jeffrey Robert AjerSVPSell1,625$126.55$205,643.75View SEC Filing  
5/18/2015Daniel K SpiegelmanCFOSell2,059$124.77$256,901.43View SEC Filing  
5/18/2015George Eric DavisSVPSell2,558$125.26$320,415.08View SEC Filing  
5/18/2015Henry J FuchsEVPSell1,864$124.78$232,589.92View SEC Filing  
5/13/2015Henry J FuchsEVPSell1,434$121.37$174,044.58View SEC Filing  
5/11/2015Henry J FuchsEVPSell2,869$121.64$348,985.16View SEC Filing  
3/17/2015Jean Jacques BienaimeCEOSell2,000$124.17$248,340.00View SEC Filing  
3/16/2015Henry J FuchsEVPSell41,315$123.57$5,105,294.55View SEC Filing  
3/16/2015Jean Jacques BienaimeCEOSell1,000$123.48$123,480.00View SEC Filing  
3/10/2015Jean Jacques BienaimeCEOSell21,021$112.39$2,362,550.19View SEC Filing  
3/9/2015Jean Jacques BienaimeCEOSell19,000$112.13$2,130,470.00View SEC Filing  
3/5/2015Jean Jacques BienaimeCEOSell10,000$113.70$1,137,000.00View SEC Filing  
3/5/2015Robert BaffiEVPSell14,051$116.37$1,635,114.87View SEC Filing  
3/4/2015Jean Jacques BienaimeCEOSell13,916$107.92$1,501,814.72View SEC Filing  
3/3/2015Jean Jacques BienaimeCEOSell5,000$107.42$537,100.00View SEC Filing  
3/2/2015Daniel K SpiegelmanCFOSell15,500$107.00$1,658,500.00View SEC Filing  
3/2/2015George Eric DavisSVPSell23,000$108.31$2,491,130.00View SEC Filing  
3/2/2015Jean Jacques BienaimeCEOSell5,000$108.44$542,200.00View SEC Filing  
1/9/2015Jean Jacques BienaimeCEOSell2,000$94.14$188,280.00View SEC Filing  
12/24/2014Jean Jacques BienaimeCEOSell5,000$88.73$443,650.00View SEC Filing  
12/10/2014Jean Jacques BienaimeCEOSell2,000$95.00$190,000.00View SEC Filing  
12/4/2014Alan LewisDirectorSell7,500$89.90$674,250.00View SEC Filing  
12/2/2014Brian MuellerVPSell11,950$90.91$1,086,374.50View SEC Filing  
11/25/2014George Eric DavisSVPSell20,000$89.75$1,795,000.00View SEC Filing  
11/25/2014Jean Jacques BienaimeCEOSell2,000$90.00$180,000.00View SEC Filing  
11/12/2014Jean Jacques BienaimeCEOSell1,000$81.51$81,510.00View SEC Filing  
11/10/2014Henry J FuchsEVPSell20,000$86.55$1,731,000.00View SEC Filing  
11/10/2014Jean Jacques BienaimeCEOSell4,000$87.00$348,000.00View SEC Filing  
11/3/2014Jean Jacques BienaimeCEOSell3,000$85.33$255,990.00View SEC Filing  
11/3/2014Jeffrey Robert AjerSVPSell47$83.54$3,926.38View SEC Filing  
10/30/2014Robert BaffiEVPSell75,425$81.34$6,135,069.50View SEC Filing  
10/24/2014Jean Jacques BienaimeCEOSell2,000$80.00$160,000.00View SEC Filing  
9/19/2014George Eric DavisSVPSell17,536$69.75$1,223,136.00View SEC Filing  
9/2/2014Daniel K SpiegelmanCFOSell16,000$69.83$1,117,280.00View SEC Filing  
8/20/2014Jean Jacques BienaimeCEOSell5,000$70.00$350,000.00View SEC Filing  
8/5/2014Henry J FuchsEVPSell10,000$65.00$650,000.00View SEC Filing  
8/1/2014Daniel K SpiegelmanCFOSell2,229$61.76$137,663.04View SEC Filing  
7/2/2014Daniel K SpiegelmanCFOSell2,229$64.00$142,656.00View SEC Filing  
6/4/2014Jean Jacques BienaimeCEOSell2,000$61.20$122,400.00View SEC Filing  
5/22/2014Jean Jacques BienaimeCEOSell1,000$56.88$56,880.00180,257View SEC Filing  
5/21/2014Jean Jacques BienaimeCEOSell1,545$56.19$86,813.55180,257View SEC Filing  
5/16/2014Henry FuchsEVPSell1,864$56.86$105,987.0460,950View SEC Filing  
5/16/2014Jeffrey Robert AjerSVPSell1,004$56.91$57,137.6420,980View SEC Filing  
5/16/2014V Bryan LawlisDirectorSell1,700$56.87$96,679.009,700View SEC Filing  
5/13/2014Henry FuchsEVPSell1,434$58.23$83,501.8264,850View SEC Filing  
5/9/2014Henry FuchsEVPSell3,479$57.91$201,468.8967,850View SEC Filing  
2/3/2014Henry FuchsEVPSell10,000$67.70$677,000.0042,350View SEC Filing  
12/24/2013Jean Jacques BienaimeCEOSell10,000$68.71$687,100.00View SEC Filing  
12/5/2013Jean Jacques BienaimeCEOSell5,000$69.70$348,500.00View SEC Filing  
10/16/2013Jean Jacques BienaimeCEOSell2,000$67.73$135,460.00View SEC Filing  
10/10/2013Jean Jacques BienaimeCEOSell3,000$66.76$200,280.00View SEC Filing  
9/19/2013Henry FuchsEVPSell10,000$80.19$801,900.0043,266View SEC Filing  
9/16/2013Jean Jacques BienaimeCEOSell2,000$73.08$146,160.00View SEC Filing  
9/9/2013Robert BaffiEVPSell20,000$73.00$1,460,000.00View SEC Filing  
9/5/2013Henry J FuchsEVPSell10,000$70.00$700,000.00View SEC Filing  
9/4/2013Daniel K SpiegelmanCFOSell9,000$69.00$621,000.00View SEC Filing  
8/15/2013Jean Jacques BienaimeCEOSell1,000$64.36$64,360.00View SEC Filing  
7/1/2013Daniel K SpiegelmanCFOSell4,066$59.78$243,065.48View SEC Filing  
7/1/2013Henry J FuchsEVPSell10,000$60.00$600,000.00View SEC Filing  
6/3/2013Henry J FuchsEVPSell1,098$58.32$64,035.36View SEC Filing  
5/23/2013Henry J FuchsEVPSell20,609$66.29$1,366,170.61View SEC Filing  
5/22/2013Mark WoodVPSell3,103$67.12$208,273.36View SEC Filing  
5/21/2013Jean Jacques BienaimeCEOSell2,000$64.14$128,280.00View SEC Filing  
5/16/2013Jean Jacques BienaimeCEOSell12,000$67.90$814,800.00View SEC Filing  
5/14/2013Brian MuellerVPSell4,947$70.35$348,021.45View SEC Filing  
5/14/2013George Eric DavisSVPSell20,000$70.34$1,406,800.00View SEC Filing  
5/14/2013Jean Jacques BienaimeCEOSell15,000$70.17$1,052,550.00View SEC Filing  
5/13/2013Jean Jacques BienaimeCEOSell15,800$68.77$1,086,566.00View SEC Filing  
5/13/2013Jeffrey Robert AjerSVPSell1,248$69.26$86,436.48View SEC Filing  
5/8/2013Jean Jacques BienaimeCEOSell4,000$65.87$263,480.00View SEC Filing  
5/2/2013Jean Jacques BienaimeCEOSell3,000$64.99$194,970.00View SEC Filing  
4/10/2013Robert BaffiEVPSell20,000$64.00$1,280,000.00View SEC Filing  
3/22/2013Mark WoodVPSell3,103$60.21$186,831.63View SEC Filing  
3/4/2013George Eric DavisSVPSell4,000$60.18$240,720.00View SEC Filing  
2/22/2013Mark WoodVPSell3,103$55.22$171,347.66View SEC Filing  
2/4/2013Jean Jacques BienaimeCEOSell2,000$55.77$111,540.00View SEC Filing  
12/27/2012Jean Jacques BienaimeCEOSell17,000$48.37$822,290.00View SEC Filing  
11/12/2012George Eric DavisSVPSell99,075$48.45$4,800,183.75View SEC Filing  
9/4/2012Henry J FuchsEVPSell5,000$37.76$188,800.00View SEC Filing  
8/22/2012Mark WoodVPSell2,665$37.93$101,083.45View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioMarin Pharmaceutical (NASDAQ BMRN) News Headlines

Source:
DateHeadline
BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales BeatBioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat
finance.yahoo.com - April 26 at 4:23 PM
BioMarin Pharmaceutical misses by $0.08, beats on revenueBioMarin Pharmaceutical misses by $0.08, beats on revenue
seekingalpha.com - April 26 at 9:30 AM
Benzingas Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin EarningsBenzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings
www.msn.com - April 26 at 9:30 AM
BioMarin Pharmaceutical (BMRN) Q1 2018 Results - Earnings Call TranscriptBioMarin Pharmaceutical (BMRN) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 9:30 AM
BioMarin: 1Q Earnings SnapshotBioMarin: 1Q Earnings Snapshot
finance.yahoo.com - April 26 at 9:30 AM
BioMarin Pharmaceutical (BMRN) CFO Daniel K. Spiegelman Sells 11,059 SharesBioMarin Pharmaceutical (BMRN) CFO Daniel K. Spiegelman Sells 11,059 Shares
www.americanbankingnews.com - April 25 at 10:16 PM
Insider Selling: BioMarin Pharmaceutical (BMRN) CEO Sells 20,000 Shares of StockInsider Selling: BioMarin Pharmaceutical (BMRN) CEO Sells 20,000 Shares of Stock
www.americanbankingnews.com - April 25 at 10:16 PM
BioMarin Pharmaceutical (BMRN) Issues Quarterly  Earnings Results, Beats Expectations By $0.22 EPSBioMarin Pharmaceutical (BMRN) Issues Quarterly Earnings Results, Beats Expectations By $0.22 EPS
www.americanbankingnews.com - April 25 at 8:40 PM
BioMarin Pharmaceutical (BMRN) Releases FY18 Earnings GuidanceBioMarin Pharmaceutical (BMRN) Releases FY18 Earnings Guidance
www.americanbankingnews.com - April 25 at 5:32 PM
How Financially Strong Is BioMarin Pharmaceutical Inc (NASDAQ:BMRN)?How Financially Strong Is BioMarin Pharmaceutical Inc (NASDAQ:BMRN)?
finance.yahoo.com - April 25 at 4:25 PM
BioMarin Announces First Quarter 2018 Financial ResultsBioMarin Announces First Quarter 2018 Financial Results
finance.yahoo.com - April 25 at 4:25 PM
3 Charts That Suggest Biotech Stocks Are Headed Lower3 Charts That Suggest Biotech Stocks Are Headed Lower
finance.yahoo.com - April 25 at 4:25 PM
BioMarin Pharmaceutical (BMRN) Cut to "Hold" at Zacks Investment ResearchBioMarin Pharmaceutical (BMRN) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 25 at 1:30 PM
Insider Selling: BioMarin Pharmaceutical (BMRN) CEO Sells 10,000 Shares of StockInsider Selling: BioMarin Pharmaceutical (BMRN) CEO Sells 10,000 Shares of Stock
www.americanbankingnews.com - April 24 at 10:22 PM
BioMarin Pharma (BMRN) Says NEJM Published Open-label Study Showing Brineura Reduced Rate of Clinical Decline of Children with CLN2 DiseaseBioMarin Pharma (BMRN) Says NEJM Published Open-label Study Showing Brineura Reduced Rate of Clinical Decline of Children with CLN2 Disease
www.streetinsider.com - April 24 at 4:19 PM
Whats in the Cards for BioMarin (BMRN) in Q1 Earnings?What's in the Cards for BioMarin (BMRN) in Q1 Earnings?
finance.yahoo.com - April 24 at 4:19 PM
Chardans Top Pick For 2018: Gene Therapy Firm UniqureChardan's Top Pick For 2018: Gene Therapy Firm Uniqure
finance.yahoo.com - April 24 at 4:19 PM
What's in the Cards for BioMarin (BMRN) in Q1 Earnings?What's in the Cards for BioMarin (BMRN) in Q1 Earnings?
finance.yahoo.com - April 24 at 4:19 PM
New England Journal of Medicine Published Open-label Study Showing Brineura® (cerliponase alfa) Reduced the Rate of Clinical Decline of Children with CLN2 Disease, a Form of Batten DiseaseNew England Journal of Medicine Published Open-label Study Showing Brineura® (cerliponase alfa) Reduced the Rate of Clinical Decline of Children with CLN2 Disease, a Form of Batten Disease
finance.yahoo.com - April 24 at 4:19 PM
BioMarin Pharmaceutical (BMRN) Stock Rating Upgraded by Zacks Investment ResearchBioMarin Pharmaceutical (BMRN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 24 at 12:47 PM
BioMarin Pharmaceutical (BMRN) Rating Lowered to Strong Sell at BidaskClubBioMarin Pharmaceutical (BMRN) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - April 24 at 11:02 AM
BioMarin Pharmaceutical (BMRN) Director Sells $318,750.00 in StockBioMarin Pharmaceutical (BMRN) Director Sells $318,750.00 in Stock
www.americanbankingnews.com - April 19 at 10:10 PM
BioMarin Pharmaceutical (BMRN) Set to Announce Quarterly Earnings on WednesdayBioMarin Pharmaceutical (BMRN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 19 at 8:46 AM
BioMarin Pharmaceuticals (BMRN) "Outperform" Rating Reiterated at BMO Capital MarketsBioMarin Pharmaceutical's (BMRN) "Outperform" Rating Reiterated at BMO Capital Markets
www.americanbankingnews.com - April 18 at 2:28 PM
4 Red-Hot Biotech Stocks to Buy Before Earnings4 Red-Hot Biotech Stocks to Buy Before Earnings
247wallst.com - April 18 at 9:55 AM
BioMarin to Host First Quarter 2018 Financial Results Conference Call and Webcast on Wednesday, April 25 at 4:30pm ETBioMarin to Host First Quarter 2018 Financial Results Conference Call and Webcast on Wednesday, April 25 at 4:30pm ET
finance.yahoo.com - April 18 at 9:55 AM
BioMarin Pharmaceutical (BMRN) Raised to "Strong-Buy" at Zacks Investment ResearchBioMarin Pharmaceutical (BMRN) Raised to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 10:55 PM
ValuEngine Downgrades BioMarin Pharmaceutical (BMRN) to SellValuEngine Downgrades BioMarin Pharmaceutical (BMRN) to Sell
www.americanbankingnews.com - April 17 at 10:55 PM
What Analysts Recommend for CymaBay TherapeuticsWhat Analysts Recommend for CymaBay Therapeutics
finance.yahoo.com - April 17 at 9:44 AM
BioMarin Pharmaceutical (BMRN) Downgraded to "Sell" at BidaskClubBioMarin Pharmaceutical (BMRN) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - April 16 at 9:16 PM
Why 4 Top Biotech Stocks May Be the Next Takeover TargetsWhy 4 Top Biotech Stocks May Be the Next Takeover Targets
247wallst.com - April 16 at 9:45 AM
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and IncyteThe Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
finance.yahoo.com - April 16 at 9:45 AM
BioMarin Pharmaceutical (BMRN) Coverage Initiated at Sanford C. BernsteinBioMarin Pharmaceutical (BMRN) Coverage Initiated at Sanford C. Bernstein
www.americanbankingnews.com - April 15 at 3:59 PM
BioMarin Pharmaceutical (BMRN) Earns Buy Rating from Deutsche BankBioMarin Pharmaceutical (BMRN) Earns Buy Rating from Deutsche Bank
www.americanbankingnews.com - April 13 at 12:59 PM
Today’s Research Reports on Trending Tickers: Array BioPharma and BioMarin PharmaceuticalToday’s Research Reports on Trending Tickers: Array BioPharma and BioMarin Pharmaceutical
finance.yahoo.com - April 13 at 9:54 AM
Did BioMarin Pharmaceutical Inc’s (NASDAQ:BMRN) Earnings Growth Outperform The Industry?Did BioMarin Pharmaceutical Inc’s (NASDAQ:BMRN) Earnings Growth Outperform The Industry?
finance.yahoo.com - April 13 at 9:54 AM
$349.42 Million in Sales Expected for BioMarin Pharmaceutical (BMRN) This Quarter$349.42 Million in Sales Expected for BioMarin Pharmaceutical (BMRN) This Quarter
www.americanbankingnews.com - April 13 at 4:08 AM
Deutsche Bank Reaffirms "Buy" Rating for BioMarin Pharmaceutical (BMRN)Deutsche Bank Reaffirms "Buy" Rating for BioMarin Pharmaceutical (BMRN)
www.americanbankingnews.com - April 12 at 3:58 PM
Zacks: Analysts Expect BioMarin Pharmaceutical Inc. (BMRN) Will Post Earnings of $0.13 Per ShareZacks: Analysts Expect BioMarin Pharmaceutical Inc. (BMRN) Will Post Earnings of $0.13 Per Share
www.americanbankingnews.com - April 11 at 8:23 AM
BioMarin Pharmaceutical (BMRN) Earns "Buy" Rating from Jefferies GroupBioMarin Pharmaceutical (BMRN) Earns "Buy" Rating from Jefferies Group
www.americanbankingnews.com - April 8 at 8:06 PM
BioMarin Pharmaceutical (BMRN) Stock Rating Lowered by Zacks Investment ResearchBioMarin Pharmaceutical (BMRN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 7 at 11:47 AM
Catalyst (CPRX) Up on New Drug Application for FirdapseCatalyst (CPRX) Up on New Drug Application for Firdapse
finance.yahoo.com - April 5 at 4:22 PM
BioMarin Pharmaceutical Inc. (BMRN) Receives Consensus Recommendation of "Buy" from AnalystsBioMarin Pharmaceutical Inc. (BMRN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 5 at 3:52 PM
BioMarin Pharmaceutical (BMRN) PT Set at $130.00 by JPMorgan ChaseBioMarin Pharmaceutical (BMRN) PT Set at $130.00 by JPMorgan Chase
www.americanbankingnews.com - April 4 at 4:42 PM
BioMarin Pharmaceutical Inc. (BMRN) EVP Sells $169,774.28 in StockBioMarin Pharmaceutical Inc. (BMRN) EVP Sells $169,774.28 in Stock
www.americanbankingnews.com - April 3 at 10:27 PM
BioMarin Pharmaceutical Inc. (BMRN) Insider Henry J. Fuchs Sells 10,000 SharesBioMarin Pharmaceutical Inc. (BMRN) Insider Henry J. Fuchs Sells 10,000 Shares
www.americanbankingnews.com - April 3 at 10:12 PM
BioMarin Pharmaceutical’s Drugs in 4Q17 and Fiscal 2017BioMarin Pharmaceutical’s Drugs in 4Q17 and Fiscal 2017
finance.yahoo.com - April 3 at 4:31 PM
Jeffrey Robert Ajer Sells 1,537 Shares of BioMarin Pharmaceutical Inc. (BMRN) StockJeffrey Robert Ajer Sells 1,537 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock
www.americanbankingnews.com - March 30 at 10:14 PM
Roche Hashes Out Details Of Patient Deaths In Hemophilia DrugRoche Hashes Out Details Of Patient Deaths In Hemophilia Drug
finance.yahoo.com - March 29 at 4:24 PM
BioMarin Pharmaceutical (BMRN) Rating Reiterated by Credit Suisse GroupBioMarin Pharmaceutical (BMRN) Rating Reiterated by Credit Suisse Group
www.americanbankingnews.com - March 29 at 12:11 PM

SEC Filings

BioMarin Pharmaceutical (NASDAQ:BMRN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioMarin Pharmaceutical (NASDAQ:BMRN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioMarin Pharmaceutical (NASDAQ BMRN) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.